Appropriate in vivo follow-up assays to an in vitro bacterial reverse mutation (Ames) test positive investigational drug candidate (active pharmaceutical ingredient), drug-related metabolite, or drug-related impurity
Timothy W. Robison(United States Food and Drug Administration), Wei Ding(Shandong First Medical University), Nan Mei(Jilin Agricultural University), Rosalie K. Elespuru(Life Sciences Discovery Fund), Mugimane G. Manjanatha(National Center for Toxicological Research), Robert H. Heflich(National Center for Toxicological Research), Aisar Atrakchi(Center for Drug Evaluation and Research)
Mutation Research/Genetic Toxicology and Environmental Mutagenesis
July 22, 2021
Cited by 20
Related Papers
A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium
|Nature Biotechnology|2014|1.1k
A rat RNA-Seq transcriptomic BodyMap across 11 organs and 4 developmental stages
|Nature Communications|2014|436
Assessment of the toxic potential of graphene family nanomaterials
|Journal of Food and Drug Analysis|2014|419
Rat toxicogenomic study reveals analytical consistency across microarray platforms
|Nature Biotechnology|2006|411